Ege University Hospital Implants Turkey’s 1st SynCardia Total Artificial Heart

Total Artificial Heart Only Suitable Device for 47-Year-Old Patient with Less Than Two Weeks to Live

TUCSON, Ariz.--(BUSINESS WIRE)-- On Sept. 30, Ege University Hospital in Izmir performed Turkey’s first implant of the SynCardia temporary Total Artificial Heart. The surgery was led by Prof. Dr. Mustafa Ozbaran, head of the Transplant and Assist Device Program, and proctored by experienced Total Artificial Heart surgeon Dr. Latif Arusoglu.

“We have extensive experience with BiVADs, but for such a sick patient, the Total Artificial Heart was the only suitable device,” said Prof. Dr. Ozbaran (photo). “The Total Artificial Heart provides a high volume of blood flow to help recover the vital organs. There is no need for inotropes, and you do not have to worry about arrhythmia.”

The 47-year-old patient, who had his mitral and atrial heart valves replaced 21 years ago, was suffering from dilated cardiomyopathy. He has been waiting for a heart transplant for two years and was moved up to emergency status two and half months ago. Prior to implant, the patient had spent three weeks in the ICU and was inotrope dependent and suffering from severe arrhythmia. Doctors expected the patient’s survival was less than 15 days without the Total Artificial Heart.

Ege University is one of the biggest and oldest universities in Turkey. The heart transplant program, started in 1998, has become the most active program in the country. Each year, Ege University performs approximately 1,100 open heart surgeries. In Turkey, the average wait time for a donor heart transplant is 18 to 24 months. Ege University is the first transplant hospital in Turkey and the 33rd in the world to become a SynCardia Certified Center.

About SynCardia Systems, Inc.

SynCardia Systems, Inc. is the Tucson-based manufacturer of the world’s only FDA, Health Canada and CE approved Total Artificial Heart: the SynCardia temporary Total Artificial Heart. There have been more than 850 implants of the Total Artificial Heart, accounting for more than 200 patient years of life on the device.

Originally used as a permanent replacement heart, the Total Artificial Heart is currently approved as a bridge to human heart transplant for people dying from end-stage biventricular failure. The Total Artificial Heart is the only device that provides immediate, safe blood flow of up to 9.5 L/min through both ventricles.

For additional information, please visit:

or follow SynCardia on Twitter – @SynCardia_News


SynCardia Systems, Inc.
Don Isaacs
Vice President of Communications
Cell: 520-955-0660

KEYWORDS:   Turkey  United States  Europe  North America  Arizona

INDUSTRY KEYWORDS:   Seniors  Women  Other Consumer  Education  University  Technology  Hardware  Software  Health  Cardiology  Hospitals  Medical Devices  Other Science  Consumer  Science  General Health  Men